As NVLX Approaches Multi-Year Highs, a Friday Short Squeeze is on the Cards


Special Breakout Alert: Nuvilex, Inc (NVLX)
Hot on the heals of a 220%+ winner
in BYSD Wednesday, I am super excited to bring you another potentially
big winner for Friday that has just broken out from multi-month
resistance and could fly much higher as it approaches multi-year highs.
Check out Nuvilex,
Inc (NVLX)
right now.

‘ve been watching NVLX for a while, waiting patiently for confirmation that it could move higher and breakout
And today (Thursday) it started to do just that, closing at $0.173 on strong volume.
But the best part is, there is still plenty of upside left. 
you can see in the chart below, multi-month highs in NVLX are around
$0.22. I would expect it to test this level in the coming day(s),
potentially breaking through to new multi-year highs above $0.22 as
momentum and trader buzz continues.
move to $0.22 would give us a very strong 29% gain – very good
considering NVLX is not particularly volatile, representing an excellent
risk/reward profile.

NVLX has been on a steady climb higher over the past six months as
buzz surrounding this biotech company increases.
One prominent small cap analyst
recently said of NVLX,
"It (the Company) is reminiscent of some of the greatest biotechnology
success stories over the past 20 years including the original biotechnology
company Genetech."
And just today, one
industry commentator suggested that NVLX is moving close to challenging
the multi-billion dollar mega pharmaceutical giant
, Eli Lilly & Co (NYSEL LLY), stating "NVLX is currently preparing the way to challenge Eli Lilly’s
blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two
independent mid-phase clinical trials, the company’s treatment involving its
proprietary living cell encapsulation technology has outperformed the
pharmaceutical giant."

>> Read more of this commentary on NVLX << 

This kind of commentary on NVLX bodes very well for momentum traders and investors looking to ride the wave higher.

Nuvilex, Inc. (NVLX)
has been a provider of all-natural products for many years. The company has
been expanded to increase its natural product-based footprint through medical
marijuana studies. They are an international biotechnology provider of live,
therapeutically valuable, encapsulated cells and services for research and
medicine. New developments by NVLX
and subsidiaries will be substantial as they have been working
on many fronts to move forward. NVLX’s
offerings will ultimately include cancer, diabetes and other treatments using
the Company’s natural product knowledge, product base, cell and gene therapy
expertise, and live-cell encapsulation technology in addition to other new
products currently under development.

a growing company that is front running the industry with its innovative

You can learn more about NVLX at their website at

There has been a lot of news, research and analysis hitting the wires on NVLX recently, you can read it all below.

We think there is plenty of upside left in NVLX over the short to medium
term. Buying at these levels could allow members to be a part of NVLX
before a potentially parabolic breakout occurs if it clears $0.22

NVLX has
proven itself to be very trader friendly. It has shown some substantial short
and long term gains, and it has tremendous liquidity and strong underlying

I’ll keep you updated on any news or thought as it comes to hand.


The Team

Click Below to Join Our Social Media Networks




————————————————————————————- DISCLAIMER —————————————————————————————

Never invest in any stock featured on our site or emails unless you can afford
to lose your entire investment.

Full disclaimer can be read at employees are not registered as an Investment Adviser in
any jurisdiction whatsoever.

The disclaimer is to be read and fully understood before using our site, or
joining our email list.

None of the materials or advertisements herein constitute offers or
solicitations to purchase or sell securities of the companies profiled herein
and any decision to invest in any such company or other financial decisions
should not be made based upon the information provide herein.  Instead strongly urges
you conduct a complete and independent investigation of the respective
companies and consideration of all pertinent risks. does not offer such advice or analysis, and further urges
you to consult your own independent tax, business, financial and investment
advisors. Investing in micro-cap and growth securities is highly speculative
and carries and extremely high degree of risk. It is possible that an
investor’s investment may be lost or impaired due to the speculative nature of
the companies profiled.

Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future

In preparing this publication,
has relied upon information supplied by its customers, and press releases which
it believes to be reliable; however, such reliability cannot be guaranteed.
Investors should not rely on the information contained in this website. Rather,
investors should use the information contained in this website as a starting
point for doing additional independent research on the featured companies. The
advertisements in this website are believed to be reliable, however, and its owners,
affiliates, subsidiaries, officers, directors, representatives and agents
disclaim any liability as to the completeness or accuracy of the information
contained in any advertisement and for any omissions of materials facts from
such advertisement.
is not responsible for any claims made by the companies advertised herein. may
receive compensation and its employees and affiliates may own stock that they
have purchased in the open market either prior, during, or after the release of
the companies profile which is an inherent conflict of interest in statements and
opinions and such statements and opinions cannot be considered independent. and its
management may benefit from any increase in the share price of the profiled
companies and hold the right to sell the shares bought at any given time
including shortly after the release of the companies profile.
may on occasion accept compensation in free-trading shares for it’s marketing
services of the company being profiled, and the third party that might have
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration.  If
ever accepts compensation in the form of free trading shares of the company
being profiled and decides to sell these shares into the public market at any
time before, during, or after the release of the companies profile our
disclaimer will be updated accordingly reflecting the current position of those
free trading shares received as compensation for our services.

/* Style Definitions */
{mso-style-name:"Table Normal";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";

244 5th Ave, New York, NY 10001

Unsubscribe | Change Subscriber Options